{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:31:53Z","timestamp":1794097913653,"version":"4.8.0"},"reference-count":453,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jhep.2025.03.017","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T20:01:44Z","timestamp":1746820904000},"page":"453-501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":159,"title":["EASL Clinical Practice Guidelines on the management of autoimmune hepatitis"],"prefix":"10.1016","volume":"83","author":[{"given":"George","family":"Dalekos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Gatselis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P.","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heneghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar W.","family":"Lohse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Londo\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Muratori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Samyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Tiniakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Lleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.03.017_bib1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jhep.2013.10.020","article-title":"Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study","volume":"60","author":"Gronbaek","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib2","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/apt.17994","article-title":"Paediatric-onset immune-mediated inflammatory disease is associated with an increased mortality risk-A nationwide study","volume":"59","author":"Malham","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.017_bib3","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib4","first-page":"1","article-title":"Hellenic association for the study of the liver clinical practice guidelines: autoimmune hepatitis","volume":"32","author":"Dalekos","year":"2019","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib6","first-page":"16334","article-title":"Recent advances in the diagnosis and management of autoimmune hepatitis","volume":"132","author":"Dalekos","year":"2022","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.jhep.2025.03.017_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2023.06.002","article-title":"Autoimmune hepatitis: epidemiology, subtypes, and presentation","volume":"28","author":"Shiffman","year":"2024","journal-title":"Clin Liver Dis"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2025.03.017_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000440747","article-title":"Role of histopathology in autoimmune hepatitis","volume":"33","author":"Tiniakos","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.jhep.2025.03.017_bib9","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/liv.15217","volume":"42","author":"Lohse","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib10","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/liv.14480","article-title":"Incidence, prevalence and mortality of autoimmune hepatitis in England 1997-2015. A population-based cohort study","volume":"40","author":"Gronbaek","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cgh.2020.05.061","article-title":"Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis","volume":"19","author":"Lamba","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102280","article-title":"Global incidence and prevalence of autoimmune hepatitis, 1970-2022: a systematic review and meta-analysis","volume":"65","author":"Hahn","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jhep.2025.03.017_bib13","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/jgh.14746","article-title":"Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population","volume":"34","author":"Lv","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/08916934.2018.1482884","article-title":"Race\/ethnicity is an independent risk factor for autoimmune hepatitis among the San Francisco underserved","volume":"51","author":"Lee","year":"2018","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jhep.2025.03.017_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/MCG.0b013e318228b781","article-title":"The impact of race\/ethnicity on the clinical epidemiology of autoimmune hepatitis","volume":"46","author":"Wong","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib16","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.cgh.2018.11.028","article-title":"Association between black race and presentation and liver-related outcomes of patients with autoimmune hepatitis","volume":"17","author":"de Boer","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/ajg.2017.456","article-title":"Hospitalizations for autoimmune hepatitis disproportionately affect black and Latino Americans","volume":"113","author":"Wen","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/flgastro-2022-102113","article-title":"Clinical implications of gender and race in patients admitted with autoimmune hepatitis: updated analysis of US hospitals","volume":"14","author":"Lee","year":"2023","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0168-8278(02)00182-4","article-title":"Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States","volume":"37","author":"Czaja","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-230X-5-27","article-title":"Autoimmune hepatitis in India: profile of an uncommon disease","volume":"5","author":"Choudhuri","year":"2005","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239964","article-title":"Clinical characteristics of paediatric autoimmune hepatitis at a referral hospital in Sub Saharan Africa","volume":"15","author":"Afaa","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.03.017_bib22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/hep.32653","article-title":"Sociodemographic and geographic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis","volume":"77","author":"Bittermann","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2014.04.022","article-title":"Genome-wide association study identifies variants associated with autoimmune hepatitis type 1","volume":"147","author":"de Boer","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.017_bib24","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.32417","article-title":"Genome-wide meta-analysis identifies susceptibility loci for autoimmune hepatitis type 1","volume":"76","author":"Li","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12876-015-0318-y","article-title":"Access to primary care is associated with better autoimmune hepatitis outcomes in an urban county hospital","volume":"15","author":"Kim","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib26","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3109\/00365521.2014.946083","article-title":"Epidemiology and clinical characteristics of autoimmune hepatitis in The Netherlands","volume":"49","author":"van Gerven","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib27","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1111\/liv.15155","article-title":"Epidemiology and surveillance of autoimmune hepatitis in Asia","volume":"42","author":"Katsumi","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib28","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/ggi.12874","article-title":"Increasing incidence of elderly-onset autoimmune hepatitis","volume":"17","author":"Morii","year":"2017","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/apt.12563","article-title":"Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly","volume":"39","author":"Chen","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.017_bib30","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/MCG.0000000000001449","article-title":"Epidemiology of autoimmune hepatitis (AIH) in the United States between 2014 and 2019: a population-based national study","volume":"55","author":"Tunio","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib31","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/liv.14900","article-title":"Autoimmune hepatitis in patients aged 70 years or older: disease characteristics, treatment response and outcome","volume":"41","author":"Dalekos","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5114\/ceh.2020.93051","article-title":"Clinical, serological, histopathological and treatment profile of autoimmune hepatitis in the elderly","volume":"6","author":"Sonthalia","year":"2020","journal-title":"Clin Exp Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib33","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.3748\/wjg.v25.i22.2809","article-title":"Autoimmune hepatitis treatment in the elderly: a systematic review","volume":"25","author":"Durazzo","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib34","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/hepr.13342","article-title":"Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan","volume":"49","author":"Tanaka","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2025.03.017_bib35","first-page":"633","article-title":"Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes","volume":"9","author":"Guy","year":"2013","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.jhep.2025.03.017_bib36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00281-018-0715-8","article-title":"Sex-related factors in autoimmune liver diseases","volume":"41","author":"Schwinge","year":"2019","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jhep.2025.03.017_bib37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1089\/jwh.2012.3972","article-title":"Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines","volume":"23","author":"Manteuffel","year":"2014","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.jhep.2025.03.017_bib38","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/MEG.0000000000000424","article-title":"Autoimmune liver disease and concomitant extrahepatic autoimmune disease","volume":"27","author":"Muratori","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/liv.13236","article-title":"Concurrent extrahepatic autoimmunity in autoimmune hepatitis: implications for diagnosis, clinical course and long-term outcomes","volume":"37","author":"Wong","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib40","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.clinre.2018.12.002","article-title":"Autoimmune hepatitis in patients with multiple sclerosis: the role of immunomodulatory treatment","volume":"43","author":"Rigopoulou","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib41","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1111\/liv.15000","article-title":"High prevalence of celiac disease in autoimmune hepatitis: systematic review and meta-analysis","volume":"41","author":"Haggard","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2018.10.014","article-title":"Extrahepatic autoimmunity in autoimmune liver disease","volume":"59","author":"Floreani","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jhep.2025.03.017_bib43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/liv.13963","article-title":"Extrahepatic autoimmune diseases in patients with autoimmune hepatitis and their relatives: a Danish nationwide cohort study","volume":"39","author":"Gronbaek","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib44","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/liv.15382","article-title":"Extrahepatic autoimmune diseases in autoimmune hepatitis: effect on mortality","volume":"42","author":"Birn-Rydder","year":"2022","journal-title":"Liver Int"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2025.03.017_bib45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000440707","article-title":"Association of extrahepatic manifestations with autoimmune hepatitis","volume":"33","author":"Wong","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.jhep.2025.03.017_bib46","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/MEG.0000000000000172","article-title":"Seroprevalence of celiac disease in patients with autoimmune hepatitis","volume":"26","author":"van Gerven","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11593150-000000000-00000","article-title":"Celiac disease in pediatric patients with autoimmune hepatitis: etiology, diagnosis, and management","volume":"14","author":"Panetta","year":"2012","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jhep.2025.03.017_bib48","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jhep.2018.10.011","article-title":"Clinical practice guidelines of the European association for the study of the liver - Advancing methodology but preserving practicability","volume":"70","author":"Cornberg","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib49","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2025.03.017_bib50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.20732","article-title":"Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome","volume":"42","author":"Feld","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib51","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/lt.25906","article-title":"Early predictors of short-term prognosis in acute and acute severe autoimmune hepatitis","volume":"26","author":"Biewenga","year":"2020","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.03.017_bib52","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1478-3231.2008.01904.x","article-title":"Features and consequences of untreated type 1 autoimmune hepatitis","volume":"29","author":"Czaja","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib53","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/LVT.0000000000000105","article-title":"Autoimmune hepatitis presenting as acute liver failure: a 20-year retrospective review of North America","volume":"29","author":"Enke","year":"2023","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.03.017_bib54","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/MEG.0000000000000353","article-title":"Fulminant presentation of autoimmune hepatitis: clinical features and early predictors of corticosteroid treatment failure","volume":"27","author":"Mendizabal","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41424-018-0028-1","article-title":"Role of age in presentation, response to therapy and outcome of autoimmune hepatitis","volume":"9","author":"Baven-Pronk","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/MPG.0000000000002892","article-title":"Presentation and outcomes of autoimmune hepatitis type 1 and type 2 in children: a single-center study","volume":"72","author":"Roepe","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib57","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jped.2018.04.007","article-title":"Autoimmune hepatitis in 828 Brazilian children and adolescents: clinical and laboratory findings, histological profile, treatments, and outcomes","volume":"95","author":"Porta","year":"2019","journal-title":"J Pediatr (Rio J)"},{"key":"10.1016\/j.jhep.2025.03.017_bib58","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/qjmed\/hch072","article-title":"Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the \u2018acute\u2019 type","volume":"97","author":"Ferrari","year":"2004","journal-title":"QJM"},{"key":"10.1016\/j.jhep.2025.03.017_bib59","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/00365520802130183","article-title":"Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study","volume":"43","author":"Werner","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib60","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3109\/15513815.2014.898721","article-title":"Autoimmune hepatitis and primary sclerosing cholangitis in children and adolescents","volume":"33","author":"Rojas","year":"2014","journal-title":"Fetal Pediatr Pathol"},{"key":"10.1016\/j.jhep.2025.03.017_bib61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.hbpd.2019.08.004","article-title":"Acute onset of autoimmune hepatitis in children and adolescents","volume":"19","author":"Smolka","year":"2020","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib62","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/hep.510250308","article-title":"Autoimmune hepatitis in childhood: a 20-year experience","volume":"25","author":"Gregorio","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib63","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12887-024-04590-9","article-title":"Retrospective, single-center analysis of autoimmune hepatitis in Jordanian children: clinical features, treatments, and outcomes","volume":"24","author":"Altamimi","year":"2024","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.jhep.2025.03.017_bib64","article-title":"Biliary disease progression in childhood onset autoimmune liver disease: a 30-year follow-up into adulthood","volume":"6","author":"Warner","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.017_bib65","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s005350050247","article-title":"Clinical features of 89 patients with autoimmune hepatitis in Nagasaki Prefecture, Japan","volume":"34","author":"Omagari","year":"1999","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib66","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jhep.2014.05.021","article-title":"Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome","volume":"61","author":"Yeoman","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib67","article-title":"Approach to the patient with acute severe autoimmune hepatitis","volume":"2","author":"Rahim","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.017_bib68","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/hep.30205","article-title":"Flare of autoimmune hepatitis causing acute on chronic liver failure: diagnosis and response to corticosteroid therapy","volume":"70","author":"Anand","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib69","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.3748\/wjg.v13.i12.1824","article-title":"Clinical heterogeneity in autoimmune acute liver failure","volume":"13","author":"Chavez-Tapia","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib70","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MPG.0000000000003268","article-title":"North American Society for pediatric Gastroenterology, Hepatology, and Nutrition position paper on the diagnosis and management of pediatric acute liver failure","volume":"74","author":"Squires","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib71","doi-asserted-by":"crossref","first-page":"e1237","DOI":"10.1542\/peds.2015-0578","article-title":"Incidence and characteristics of autoimmune hepatitis","volume":"136","author":"Jimenez-Rivera","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.jhep.2025.03.017_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2020.100594","article-title":"Autoimmune hepatitis in Cuban patients: a retrospective analysis of clinical and histological profiles, treatments, and outcomes","volume":"93","author":"Castellanos Fernandez","year":"2020","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.jhep.2025.03.017_bib73","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/liv.15829","article-title":"The evolving phenotype of autoimmune hepatitis across the millennium: the 40-year experience of a referral centre in Italy","volume":"44","author":"Ferronato","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib74","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","article-title":"Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group","volume":"41","author":"Vergani","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib75","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejim.2017.10.006","article-title":"Serology in autoimmune hepatitis: a clinical-practice approach","volume":"48","author":"Terziroli Beretta-Piccoli","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jhep.2025.03.017_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-070201","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"380","author":"Muratori","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2025.03.017_bib77","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2022.11.013","article-title":"Autoimmune serology testing in clinical practice: an updated roadmap for the diagnosis of autoimmune hepatitis","volume":"108","author":"Dalekos","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jhep.2025.03.017_bib78","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jcla.21813","article-title":"Autoantibody profiling in a cohort of pediatric and adult patients with autoimmune hepatitis","volume":"30","author":"Villalta","year":"2016","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.jhep.2025.03.017_bib79","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(87)92024-1","article-title":"Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen","volume":"1","author":"Manns","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.03.017_bib80","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPG.0000000000001801","article-title":"Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN Hepatology committee position statement","volume":"66","author":"Mieli-Vergani","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib81","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/jhep.2002.32092","article-title":"Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease","volume":"35","author":"Ma","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib82","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/liv.14280","article-title":"Permanent immunosuppression in SLA\/LP-positive autoimmune hepatitis is required although overall response and survival are similar","volume":"40","author":"Zachou","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib83","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1478-3231.2011.02502.x","article-title":"Prognostic implications of antibodies to Ro\/SSA and soluble liver antigen in type 1 autoimmune hepatitis","volume":"32","author":"Montano-Loza","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib84","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/liv.12658","article-title":"Anti-SLA\/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis","volume":"35","author":"Zachou","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib85","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jhep.2023.01.013","article-title":"Long-term outcomes of patients with type 1 or 2 autoimmune hepatitis presenting in childhood","volume":"78","author":"Maggiore","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib86","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jhep.2023.02.017","article-title":"Paediatric autoimmune hepatitis: time to change the textbooks?","volume":"78","author":"Lohse","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib87","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0168-8278(99)80342-0","article-title":"Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis","volume":"31","author":"Kanzler","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib88","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0168-8278(00)80361-X","article-title":"Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis","volume":"33","author":"Ballot","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib89","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0168-8278(00)80421-3","article-title":"Chronic cholestatic diseases","volume":"32","author":"Poupon","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib90","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib91","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000123","article-title":"Immune signatures in variant syndromes of primary biliary cholangitis and autoimmune hepatitis","volume":"7","author":"Schultheiss","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.03.017_bib92","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jhep.2023.02.030","article-title":"Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: a coming of age or an age-ist problem?","volume":"79","author":"Ricciuto","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib93","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL clinical practice guidelines on sclerosing cholangitis","volume":"77","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib94","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib95","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1034\/j.1600-0641.2000.033004543.x","article-title":"High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis","volume":"33","author":"van Buuren","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib96","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.26454","article-title":"Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history","volume":"58","author":"Deneau","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib97","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00005-019-00550-9","article-title":"Variant and specific forms of autoimmune cholestatic liver diseases","volume":"67","author":"Dalekos","year":"2019","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.jhep.2025.03.017_bib98","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib99","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fimmu.2018.00609","article-title":"Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance","volume":"9","author":"Sebode","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.03.017_bib100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejim.2023.06.001","article-title":"Prevalence and significance of antimitochondrial antibodies in autoimmune hepatitis (AIH): results from a large multicentre study of the International AIH Group","volume":"116","author":"Gatselis","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jhep.2025.03.017_bib101","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouilleres","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib102","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/hep4.1148","article-title":"New scoring classification for primary biliary cholangitis-autoimmune hepatitis overlap syndrome","volume":"2","author":"Zhang","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.03.017_bib103","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/MEG.0000000000000075","article-title":"Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis","volume":"26","author":"Efe","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib104","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jhep.2021.06.035","article-title":"Acute-on-chronic liver failure: a complex clinical entity in patients with autoimmune hepatitis","volume":"75","author":"Granito","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib105","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.dld.2019.01.015","article-title":"Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: a nationwide register-based cohort study in Finland","volume":"51","author":"Puustinen","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2025.03.017_bib106","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cgh.2017.02.006","article-title":"Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis","volume":"15","author":"Tansel","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib107","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s12072-021-10249-9","article-title":"Sex and regional disparities in incidence of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis","volume":"15","author":"Yan","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib108","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.jhep.2024.03.025","article-title":"Italian Liver Cancer (ITA.LI.CA) Group. Hepatocellular carcinoma in patients with autoimmune hepatitis","volume":"81","author":"Pasta","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib109","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s10620-018-5441-5","article-title":"Older age and disease duration are highly associated with hepatocellular carcinoma in patients with autoimmune hepatitis","volume":"64","author":"Dakhoul","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.03.017_bib110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jhep.2023.09.010","article-title":"Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis","volume":"80","author":"Colapietro","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib111","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.1840180435","article-title":"Meeting report: international autoimmune hepatitis group","volume":"18","author":"Johnson","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib112","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib113","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib114","article-title":"Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease","volume":"5","author":"Zachou","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.017_bib115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejim.2020.12.024","article-title":"Alcoholic liver disease and autoimmune hepatitis: sometimes a closer look under the surface is needed","volume":"85","author":"Rigopoulou","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jhep.2025.03.017_bib116","article-title":"Non-organ-specific autoantibodies with unspecific patterns are a frequent para-infectious feature of chronic hepatitis D","volume":"10","author":"Hermanussen","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jhep.2025.03.017_bib117","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1665-2681(19)30914-7","article-title":"Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome","volume":"13","author":"Rigopoulou","year":"2013","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib118","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.3748\/wjg.v19.i23.3629","article-title":"Role of international criteria in the diagnosis of autoimmune hepatitis","volume":"19","author":"Abdollahi","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib119","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jceh.2018.10.006","article-title":"Accuracy of the simplified criteria for autoimmune hepatitis in children: systematic review and decision analysis","volume":"9","author":"Arcos-Machancoses","year":"2019","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib120","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5223\/pghn.2018.21.2.118","article-title":"Accuracy of the 2008 simplified criteria for the diagnosis of autoimmune hepatitis in children","volume":"21","author":"Arcos-Machancoses","year":"2018","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib121","doi-asserted-by":"crossref","first-page":"772","DOI":"10.5604\/01.3001.0010.2787","article-title":"Validation of the simplified criteria for the diagnosis of autoimmune hepatitis in Chilean-Hispanic patients","volume":"16","author":"Candia","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib122","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/hep.22513","article-title":"Performance parameters of the diagnostic scoring systems for autoimmune hepatitis","volume":"48","author":"Czaja","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib123","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jhep.2010.06.032","article-title":"Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients","volume":"54","author":"Qiu","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib124","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/hep.23042","article-title":"Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease","volume":"50","author":"Yeoman","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib125","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/liv.14778","article-title":"Limitation of the simplified scoring system for the diagnosis of autoimmune hepatitis with acute onset","volume":"41","author":"Muratori","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib126","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.dld.2010.03.005","article-title":"Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score?","volume":"42","author":"Gatselis","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2025.03.017_bib127","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3350\/cmh.2023.0325","article-title":"Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity","volume":"30","author":"Ahn","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib128","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1111\/liv.15394","article-title":"Recommendations for histological criteria of autoimmune hepatitis from the international AIH pathology: validation on a monocentric cohort","volume":"42","author":"Colapietro","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3350\/cmh.2024.0131","article-title":"Evaluation of the histological scoring systems of autoimmune hepatitis: a significant step towards the optimization of clinical diagnosis","volume":"30","author":"Komori","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib130","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2011.11.030","article-title":"Validation and modification of simplified diagnostic criteria for autoimmune hepatitis in children","volume":"10","author":"Mileti","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib131","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/MPG.0b013e3181fc1e0b","article-title":"Utility of simplified criteria for the diagnosis of autoimmune hepatitis in children","volume":"52","author":"Hiejima","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib132","doi-asserted-by":"crossref","first-page":"526","DOI":"10.5152\/tjg.2021.19305","article-title":"Evaluation of validity and efficiency of diagnostic criteria in autoimmune hepatitis in children","volume":"32","author":"Imanieh","year":"2021","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib133","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1097\/MPG.0000000000002050","article-title":"Spectrum of pediatric autoimmune liver disease and validation of its diagnostic scores in Indian children","volume":"67","author":"Sood","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib134","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhep.2020.07.032","article-title":"Update of the simplified criteria for autoimmune hepatitis: evaluation of the methodology for immunoserological testing","volume":"74","author":"Galaski","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cgh.2015.07.017","article-title":"Features and progression of asymptomatic autoimmune hepatitis in Italy","volume":"14","author":"Muratori","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib136","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s00535-010-0316-3","article-title":"Clinicopathological features of severe and fulminant forms of autoimmune hepatitis","volume":"46","author":"Yasui","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib137","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-71296-0","article-title":"Increasing incidence of acute autoimmune hepatitis: a nationwide survey in Japan","volume":"10","author":"Takahashi","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2025.03.017_bib138","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cgh.2006.10.011","article-title":"Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis","volume":"5","author":"Abe","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib139","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jhep.2009.01.020","article-title":"Autoimmune hepatitis in Italy: the Bologna experience","volume":"50","author":"Muratori","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib140","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00535-008-2254-x","article-title":"Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis","volume":"43","author":"Fujiwara","year":"2008","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib141","article-title":"Features and outcome of AIH patients without elevation of IgG","volume":"2","author":"Hartl","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.017_bib142","first-page":"101","article-title":"Serum immunoglobulin levels in healthy children and adults","volume":"4","author":"Stoop","year":"1969","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jhep.2025.03.017_bib143","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/ard.2006.066027","article-title":"New markers and an old phenomenon: prozone effect disturbing detection of filaggrin (keratin) autoantibodies","volume":"66","author":"Dubois-Galopin","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jhep.2025.03.017_bib144","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/S0140-6736(00)02166-8","article-title":"Identification of target antigen for SLA\/LP autoantibodies in autoimmune hepatitis","volume":"355","author":"Wies","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.03.017_bib145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gut.51.2.259","article-title":"Establishment of standardised SLA\/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics","volume":"51","author":"Baeres","year":"2002","journal-title":"Gut"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2025.03.017_bib146","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000440748","article-title":"Autoantibodies in autoimmune hepatitis","volume":"33","author":"Muratori","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.jhep.2025.03.017_bib147","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/1744666X.2017.1327355","article-title":"Diagnostic approach to autoimmune hepatitis","volume":"13","author":"Muratori","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jhep.2025.03.017_bib148","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/MEG.0000000000002747","article-title":"The frequency and clinical significance of antibodies to soluble liver antigen\/liver pancreas in autoimmune hepatitis: a prospective single-center study","volume":"36","author":"Yuksekyayla","year":"2024","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib149","article-title":"Meta-analysis: diagnostic accuracy of antinuclear antibodies, smooth muscle antibodies and antibodies to a soluble liver antigen\/liver pancreas in autoimmune hepatitis","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.03.017_bib150","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10620-010-1501-1","article-title":"Performance parameters of the conventional serological markers for autoimmune hepatitis","volume":"56","author":"Czaja","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.03.017_bib151","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41584-021-00573-7","article-title":"Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis","volume":"17","author":"Granito","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib152","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/ajg.2009.126","article-title":"The serological profile of the autoimmune hepatitis\/primary biliary cirrhosis overlap syndrome","volume":"104","author":"Muratori","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib153","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41584-020-0480-7","article-title":"New insights into the role of antinuclear antibodies in systemic lupus erythematosus","volume":"16","author":"Pisetsky","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib154","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137927","article-title":"Two of them do it better: novel serum biomarkers improve autoimmune hepatitis diagnosis","volume":"10","author":"Mazzara","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.03.017_bib155","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-1-61779-959-4_15","article-title":"Identification of new autoimmune hepatitis-specific autoantigens by using protein microarray technology","volume":"909","author":"Wu","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jhep.2025.03.017_bib156","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1074\/mcp.M112.018713","article-title":"Identification of new autoantigens by protein array indicates a role for IL4 neutralization in autoimmune hepatitis","volume":"11","author":"Zingaretti","year":"2012","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.jhep.2025.03.017_bib157","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hep.32134","article-title":"Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis","volume":"75","author":"Taubert","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib158","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1007\/s12072-024-10695-1","article-title":"Detection of polyreactive immunoglobulin G facilitates diagnosis in children with autoimmune hepatitis","volume":"18","author":"Engel","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib159","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/HEP.0000000000000767","article-title":"NMR-based metabolomic signature: an important tool for the diagnosis and study of pathogenesis of autoimmune hepatitis","volume":"80","author":"Dimou","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib160","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/gutjnl-2020-321299","article-title":"Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of pathology","volume":"69","author":"Neuberger","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.017_bib161","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/MPG.0000000000000632","article-title":"Liver biopsy in children: position paper of the ESPGHAN Hepatology Committee","volume":"60","author":"Dezsofi","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib162","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib163","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jhep.2021.12.041","article-title":"Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group","volume":"76","author":"Pape","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib164","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejim.2021.03.024","article-title":"Drug withdrawal in patients with autoimmune hepatitis in long-term histological remission: a prospective observational study","volume":"90","author":"van den Brand","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jhep.2025.03.017_bib165","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3748\/wjg.v29.i12.1838","article-title":"Autoimmune liver diseases and SARS-CoV-2","volume":"29","author":"Sgamato","year":"2023","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib166","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jhep.2023.04.033","article-title":"Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report","volume":"79","author":"Andrade","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib167","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cgh.2006.09.034","article-title":"Celiac disease and risk of liver disease: a general population-based study","volume":"5","author":"Ludvigsson","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib168","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib169","doi-asserted-by":"crossref","first-page":"12662","DOI":"10.3748\/wjg.v20.i35.12662","article-title":"Association of autoimmune hepatitis and systemic lupus erythematodes: a case series and review of the literature","volume":"20","author":"Beisel","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"Suppl 134","key":"10.1016\/j.jhep.2025.03.017_bib170","doi-asserted-by":"crossref","first-page":"93","DOI":"10.55563\/clinexprheumatol\/jrz47c","article-title":"Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation","volume":"40","author":"Tani","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib171","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib172","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/hep4.1959","article-title":"Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports","volume":"6","author":"Bjornsson","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.03.017_bib173","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2016.05.043","article-title":"Features of autoimmune hepatitis in patients with drug-induced liver injury","volume":"15","author":"de Boer","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib174","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: clinical characteristics and prognosis","volume":"51","author":"Bjornsson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib175","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1055\/s-0034-1375959","article-title":"Drug-induced liver injury with autoimmune features","volume":"34","author":"deLemos","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2025.03.017_bib176","article-title":"Histological and serological features of acute liver injury after SARS-CoV-2 vaccination","volume":"5","author":"Codoni","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.017_bib177","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/hep.32572","article-title":"Liver injury after SARS-CoV-2 vaccination: features of immune-mediated hepatitis, role of corticosteroid therapy and outcome","volume":"76","author":"Efe","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib178","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/hep.32327","article-title":"A revised electronic version of RUCAM for the diagnosis of DILI","volume":"76","author":"Hayashi","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib179","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.24481","article-title":"The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury","volume":"54","author":"Suzuki","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib180","doi-asserted-by":"crossref","first-page":"21","DOI":"10.14218\/JCTH.2018.00053","article-title":"Liver fibrosis helps to distinguish autoimmune hepatitis from DILI with autoimmune features: a review of twenty cases","volume":"7","author":"Febres-Aldana","year":"2019","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib181","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/liv.15623","article-title":"Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries","volume":"43","author":"Garcia-Cortes","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib182","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.cgh.2016.07.022","article-title":"Characterizing drug-induced liver injury with autoimmune features","volume":"14","author":"Andrade","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib183","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2012.12.025","article-title":"Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases","volume":"11","author":"Ghabril","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib184","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.3748\/wjg.v21.i24.7584","article-title":"Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases","volume":"21","author":"Rodrigues","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib185","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.cgh.2017.05.027","article-title":"Drug-induced autoimmune hepatitis: response to corticosteroids and lack of relapse after cessation of steroids","volume":"15","author":"Bjornsson","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib186","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jhep.2021.08.024","article-title":"Infliximab-induced liver injury: clinical phenotypes, autoimmunity and the role of corticosteroid treatment","volume":"76","author":"Bjornsson","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib187","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.017_bib188","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(73)92125-9","article-title":"Controlled trial of prednisone and azathioprine in active chronic hepatitis","volume":"1","author":"Murray-Lyon","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.03.017_bib189","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/oxfordjournals.qjmed.a067264","article-title":"Controlled prospective trial of corticosteroid therapy in active chronic hepatitis","volume":"40","author":"Cook","year":"1971","journal-title":"Q J Med"},{"key":"10.1016\/j.jhep.2025.03.017_bib190","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/gut.21.1.78","article-title":"Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis","volume":"21","author":"Kirk","year":"1980","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.017_bib191","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cgh.2010.10.013","article-title":"Immunosuppressive therapy allows recovery from liver failure in children with autoimmune hepatitis","volume":"9","author":"Cuarterolo","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib192","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7869\/tg.243","article-title":"Autoimmune hepatitis in India: single tertiary referral centre experience","volume":"36","author":"Amarapurkar","year":"2015","journal-title":"Trop Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib193","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/liv.14082","article-title":"Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country","volume":"39","author":"Choi","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib194","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jpeds.2019.11.028","article-title":"Seamless management of juvenile autoimmune liver disease: long-term medical and social outcome","volume":"218","author":"Di Giorgio","year":"2020","journal-title":"J Pediatr"},{"key":"10.1016\/j.jhep.2025.03.017_bib195","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12072-014-9558-0","article-title":"Characteristics and outcome of autoimmune liver disease in Asian children","volume":"9","author":"Lee","year":"2015","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib196","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jpeds.2020.10.009","article-title":"Autoimmune hepatitis: predictors of native liver survival in children and adolescents","volume":"229","author":"Porta","year":"2021","journal-title":"J Pediatr"},{"key":"10.1016\/j.jhep.2025.03.017_bib197","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/HEP.0000000000000589","article-title":"Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry","volume":"79","author":"Slooter","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib198","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1016\/j.cgh.2020.10.006","article-title":"Increased mortality risk in autoimmune hepatitis: a nationwide population-based cohort study with histopathology","volume":"19","author":"Sharma","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib199","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.cgh.2018.09.046","article-title":"Increased mortality among patients with vs without cirrhosis and autoimmune hepatitis","volume":"17","author":"van den Brand","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib200","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12876-023-03105-7","article-title":"Evaluation of autoimmune liver disease natural history in patients referred to Middle East Liver Diseases (MELD) center","volume":"24","author":"Nejad","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib201","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00535-016-1267-0","article-title":"Autoimmune hepatitis in Japan: trends in a nationwide survey","volume":"52","author":"Takahashi","year":"2017","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib202","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.cgh.2021.05.024","article-title":"Aminotransferases during treatment predict long-term survival in patients with autoimmune hepatitis type 1: a landmark analysis","volume":"20","author":"Biewenga","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib203","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.dld.2020.04.012","article-title":"Normalization of serum immunoglobulin G levels is associated with improved transplant-free survival in patients with autoimmune hepatitis","volume":"52","author":"Gerussi","year":"2020","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2025.03.017_bib204","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.cgh.2019.11.013","article-title":"Rapid response to treatment of autoimmune hepatitis associated with remission at 6 and 12 Months","volume":"18","author":"Pape","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib205","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jhep.2006.04.007","article-title":"Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre","volume":"45","author":"Al-Chalabi","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib206","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1572-0241.2001.03782.x","article-title":"Autoimmune hepatitis in the elderly","volume":"96","author":"Schramm","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib207","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/jbmr.4289","article-title":"Bone microarchitecture in patients with autoimmune hepatitis","volume":"36","author":"Schmidt","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jhep.2025.03.017_bib208","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cgh.2019.05.043","article-title":"A system to determine risk of osteoporosis in patients with autoimmune hepatitis","volume":"18","author":"Schmidt","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib209","doi-asserted-by":"crossref","first-page":"127","DOI":"10.14309\/ajg.0000000000002354","article-title":"Increased risk of osteoporotic fracture in patients with autoimmune hepatitis","volume":"119","author":"Lim","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib210","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/IJG.0000000000001352","article-title":"Effect of long-term oral steroids on intraocular pressure in children with autoimmune hepatitis: a prospective cohort study","volume":"28","author":"Prasad","year":"2019","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jhep.2025.03.017_bib211","doi-asserted-by":"crossref","first-page":"e1430","DOI":"10.1111\/aos.14820","article-title":"Risk of ocular hypertension in children treated with systemic glucocorticoid","volume":"99","author":"Krag","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jhep.2025.03.017_bib212","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2010.01.037","article-title":"Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials","volume":"53","author":"Lamers","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib213","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/hepr.12397","article-title":"Rapid corticosteroid tapering: important risk factor for type 1 autoimmune hepatitis relapse in Japan","volume":"45","author":"Takahashi","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2025.03.017_bib214","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1186\/s13063-022-06890-w","article-title":"Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial","volume":"23","author":"Snijders","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.jhep.2025.03.017_bib215","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41423-021-00768-8","article-title":"Autoimmmune hepatitis","volume":"19","author":"Terziroli Beretta-Piccoli","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jhep.2025.03.017_bib216","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.cgh.2018.12.035","article-title":"Predniso(lo)ne dosage and chance of remission in patients with autoimmune hepatitis","volume":"17","author":"Pape","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib217","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018313","article-title":"The efficacy and safety of different doses of glucocorticoid for autoimmune hepatitis: a systematic review and meta-analysis","volume":"98","author":"Zhang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhep.2025.03.017_bib218","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/MEG.0000000000001930","article-title":"Efficiency of azathioprine monotherapy for maintenance treatment of autoimmune hepatitis in children","volume":"34","author":"Aksoy","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib219","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1136\/flgastro-2020-101661","article-title":"Provision and standards of care for treatment and follow-up of patients with Autoimmune Hepatitis (AIH)","volume":"13","author":"Gordon","year":"2022","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib220","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJM199510123331502","article-title":"Azathioprine for long-term maintenance of remission in autoimmune hepatitis","volume":"333","author":"Johnson","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.017_bib221","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2024.03.021","article-title":"Treatment response and clinical event-free survival in autoimmune hepatitis: a Canadian multicentre cohort study","volume":"81","author":"Plagiannakos","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib222","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jhep.2012.09.009","article-title":"Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission","volume":"58","author":"van Gerven","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib223","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1111\/liv.16035","article-title":"Unmet needs in autoimmune hepatitis: results of the prospective multicentre European Reference Network Registry (R-LIVER)","volume":"44","author":"Schregel","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib224","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/gut.16.11.876","article-title":"Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared","volume":"16","author":"Summerskill","year":"1975","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.017_bib225","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2010.12.032","article-title":"Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients","volume":"55","author":"Zachou","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib226","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cgh.2008.04.006","article-title":"A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis","volume":"6","author":"Hlivko","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib227","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/apt.13584","article-title":"A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis","volume":"43","author":"Zachou","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.017_bib228","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/MEG.0000000000001367","article-title":"Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis","volume":"31","author":"Yu","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib229","article-title":"First results from a propensity matching trial of mycophenolate mofetil vs. azathioprine in treatment-naive AIH patients","volume":"12","author":"Dalekos","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.03.017_bib230","article-title":"Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis","volume":"4","author":"Dalekos","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.017_bib231","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jhep.2023.11.032","article-title":"An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis","volume":"80","author":"Snijders","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib232","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1111\/liv.14513","article-title":"High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation","volume":"40","author":"Pape","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib233","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jhep.2020.07.023","article-title":"Second-line and third-line therapy for autoimmune hepatitis: a position statement from the European reference network on hepatological diseases and the international autoimmune hepatitis group","volume":"73","author":"Lohse","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib234","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13052-024-01639-4","article-title":"Prevalence of autoimmune thyroiditis among children with autoimmune hepatitis","volume":"50","author":"Mogahed","year":"2024","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.jhep.2025.03.017_bib235","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10620-022-07525-5","article-title":"Patient priorities in autoimmune hepatitis: the need for better treatments, more education and challenging stigma","volume":"68","author":"Lloyd","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.03.017_bib236","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170259","article-title":"Systematic review of the toxicity of long-course oral corticosteroids in children","volume":"12","author":"Aljebab","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.03.017_bib237","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.02.001","article-title":"NAFLD and autoimmune hepatitis: do not judge a book by its cover","volume":"75","author":"Dalekos","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jhep.2025.03.017_bib238","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jgh3.12046","article-title":"Non-alcoholic fatty liver disease in patients with autoimmune hepatitis","volume":"2","author":"Takahashi","year":"2018","journal-title":"JGH Open"},{"key":"10.1016\/j.jhep.2025.03.017_bib239","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib240","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/hep.24743","article-title":"Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand","volume":"55","author":"Ngu","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib241","doi-asserted-by":"crossref","first-page":"129","DOI":"10.14309\/ajg.0000000000001525","article-title":"Increased cancer risk in autoimmune hepatitis: a Danish nationwide cohort study","volume":"117","author":"Jensen","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib242","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jhep.2016.05.023","article-title":"Transient elastography in autoimmune hepatitis: timing determines the impact of inflammation and fibrosis","volume":"65","author":"Hartl","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib243","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.12659\/MSM.907300","article-title":"Transient elastography (FibroScan) performs better than non-invasive markers in assessing liver fibrosis and cirrhosis in autoimmune hepatitis patients","volume":"23","author":"Guo","year":"2017","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jhep.2025.03.017_bib244","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/jgh.13508","article-title":"Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis","volume":"32","author":"Xu","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib245","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jhep.2017.11.020","article-title":"Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis","volume":"68","author":"Hartl","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib246","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2020.10.013","article-title":"FibroMeter scores for the assessment of liver fibrosis in patients with autoimmune liver diseases","volume":"22","author":"Zachou","year":"2021","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib247","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/liv.14726","article-title":"Measurement of liver and spleen stiffness as complementary methods for assessment of liver fibrosis in autoimmune hepatitis","volume":"41","author":"Janik","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib248","doi-asserted-by":"crossref","first-page":"101213","DOI":"10.1016\/j.jhepr.2024.101213","article-title":"Liver stiffness after 6 months of treatment predicts clinical outcomes in autoimmune hepatitis","volume":"6","author":"Olivas","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.017_bib249","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1478-3231.2005.01122.x","article-title":"Budesonide in previously untreated autoimmune hepatitis","volume":"25","author":"Wiegand","year":"2005","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib250","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.017_bib251","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jpeds.2013.05.042","article-title":"Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents","volume":"163","author":"Woynarowski","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.jhep.2025.03.017_bib252","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/HEP.0000000000000018","article-title":"Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration","volume":"77","author":"Diaz-Gonzalez","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib253","first-page":"4838","article-title":"Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: a systematic review and network meta-analysis","volume":"15","author":"Lu","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jhep.2025.03.017_bib254","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cgh.2016.12.040","article-title":"Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis","volume":"16","author":"Peiseler","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib255","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1034\/j.1600-0676.2003.00810.x","article-title":"Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis","volume":"23","author":"Czaja","year":"2003","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib256","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/MCG.0b013e318154af74","article-title":"Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis","volume":"42","author":"Luth","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib257","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/ajg.2015.139","article-title":"Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis","volume":"110","author":"Dhaliwal","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib258","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/liv.14051","article-title":"Stopping immunosuppressive treatment in autoimmune hepatitis (AIH): is it justified (and in whom and when)?","volume":"39","author":"Harrison","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib259","doi-asserted-by":"crossref","first-page":"498","DOI":"10.14309\/ajg.0000000000000538","article-title":"Immunosuppression in autoimmune hepatitis: is there an end game?","volume":"115","author":"Moon","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib260","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/hep.27983","article-title":"Prediction of short- and long-term outcome in patients with autoimmune hepatitis","volume":"62","author":"Kirstein","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib261","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2014.10.018","article-title":"Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis","volume":"62","author":"Hartl","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib262","article-title":"Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis","volume":"3","author":"Laschtowitz","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.017_bib263","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101772","article-title":"Non-invasive diagnosis and follow-up of autoimmune hepatitis","volume":"46","author":"Lemoinne","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib264","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep4.1889","article-title":"Noninvasive prediction of outcomes in autoimmune hepatitis-related cirrhosis","volume":"6","author":"Llovet","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.03.017_bib265","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s10620-010-1243-0","article-title":"Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal","volume":"55","author":"Czaja","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.03.017_bib266","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(85)91329-7","article-title":"Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis","volume":"1","author":"Stellon","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.03.017_bib267","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/hep.1840080414","article-title":"Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal","volume":"8","author":"Stellon","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib268","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep4.1275","article-title":"Chloroquine is effective for maintenance of remission in autoimmune hepatitis: controlled, double-blind, randomized trial","volume":"3","author":"Raquel Benedita Terrabuio","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.03.017_bib269","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1111\/liv.15241","article-title":"Treatment and outcome of autoimmune hepatitis (AIH): audit of 28 UK centres","volume":"42","author":"Gordon","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib270","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/hepr.13252","article-title":"Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis","volume":"49","author":"Zachou","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2025.03.017_bib271","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0168-8278(00)00095-7","article-title":"Duration of immunosuppressive therapy in autoimmune hepatitis","volume":"34","author":"Kanzler","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib272","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/FTD.0000000000000848","article-title":"Systematic review and meta-analysis of thiopurine metabolite levels and biochemical remission in autoimmune hepatitis","volume":"43","author":"Bolia","year":"2021","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jhep.2025.03.017_bib273","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s12072-023-10482-4","article-title":"Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute-on-chronic liver failure","volume":"17","author":"Sharma","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib274","first-page":"532","article-title":"Acute non-A, non-B, non-C hepatitis differences and similarities between hepatitis E virus infection and autoimmune hepatitis, with phylogenetic analysis of hepatitis E virus in humans and wild boars","volume":"35","author":"Zachou","year":"2022","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib275","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.2169\/internalmedicine.51.8372","article-title":"Clinical features of cirrhosis in Japanese patients with type I autoimmune hepatitis","volume":"51","author":"Abe","year":"2012","journal-title":"Intern Med"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2025.03.017_bib276","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000440756","article-title":"Treatment withdrawal in autoimmune hepatitis","volume":"33","author":"Bouma","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.jhep.2025.03.017_bib277","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e03767","article-title":"Prognostic factors for remission, relapse, and treatment complications in type 1 autoimmune hepatitis","volume":"6","author":"Sandusadee","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.jhep.2025.03.017_bib278","doi-asserted-by":"crossref","DOI":"10.1177\/03946320221077860","article-title":"Is there any predictor for relapse after treatment withdrawal in autoimmune hepatitis patients in the real life?","volume":"36","author":"Cavus","year":"2022","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jhep.2025.03.017_bib279","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jpeds.2013.12.008","article-title":"Outcome after discontinuation of immunosuppression in children with autoimmune hepatitis: a population-based study","volume":"164","author":"Deneau","year":"2014","journal-title":"J Pediatr"},{"key":"10.1016\/j.jhep.2025.03.017_bib280","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/MPG.0000000000001125","article-title":"Clinical characteristics and prognosis in children and adolescents with autoimmune hepatitis and overlap syndrome","volume":"63","author":"Rodrigues","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib281","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/MPG.0000000000001563","article-title":"Outcomes in pediatric autoimmune hepatitis and significance of azathioprine metabolites","volume":"65","author":"Sheiko","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib282","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jhep.2012.07.032","article-title":"Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors","volume":"57","author":"Sockalingam","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib283","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/liv.15440","article-title":"Confidence in treatment is contributing to quality of life in autoimmune liver diseases. The results of ERN RARE-LIVER online survey","volume":"43","author":"Wunsch","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib284","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jhep.2021.03.023","article-title":"Towards personalised medicine in autoimmune hepatitis: measurement of thiopurine metabolites results in higher biochemical response rates","volume":"75","author":"Candels","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib285","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/HEP.0000000000000940","article-title":"Optimizing thiopurine therapy in autoimmune hepatitis: a multicenter study on monitoring metabolite profiles and co-therapy with allopurinol","volume":"80","author":"Weltzsch","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib286","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/apt.15157","article-title":"Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis","volume":"49","author":"Santiago","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.017_bib287","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2022.100172","article-title":"Mycophenolate mofetil as second line treatment in autoimmune hepatitis - a retrospective single center analysis","volume":"5","author":"Kolev","year":"2022","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.jhep.2025.03.017_bib288","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/apt.15248","article-title":"Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels","volume":"49","author":"Nicoll","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.017_bib289","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04727.x","article-title":"The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes","volume":"34","author":"Baven-Pronk","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.017_bib290","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.cgh.2017.06.001","article-title":"Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis","volume":"15","author":"Efe","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib291","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2017.09.063","article-title":"Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy","volume":"16","author":"Roberts","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib292","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","article-title":"Mycophenolate mofetil as second line therapy in autoimmune hepatitis?","volume":"103","author":"Hennes","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib293","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cgh.2015.09.037","article-title":"Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance","volume":"14","author":"Hubener","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib294","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/apt.14939","article-title":"Biochemical efficacy of tioguanine in autoimmune hepatitis: a retrospective review of practice in The Netherlands","volume":"48","author":"van den Brand","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.017_bib295","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/MEG.0000000000001019","article-title":"A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment","volume":"30","author":"De Lemos-Bonotto","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib296","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.3748\/wjg.v23.i33.6030","article-title":"Autoimmune hepatitis: standard treatment and systematic review of alternative treatments","volume":"23","author":"Terziroli Beretta-Piccoli","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib297","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/MPG.0000000000001530","article-title":"Second-line agents in pediatric patients with autoimmune hepatitis: a systematic review and meta-analysis","volume":"65","author":"Zizzo","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib298","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/MEG.0000000000001580","article-title":"Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience","volume":"32","author":"Pape","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib299","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1007\/s10620-020-06569-9","article-title":"Tacrolimus as an effective and durable second-line treatment for chronic autoimmune hepatitis: a multicentric study","volume":"66","author":"Ferre-Aracil","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.03.017_bib300","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/apt.14968","article-title":"Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom","volume":"48","author":"Dyson","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.017_bib301","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.jhep.2022.09.026","article-title":"2022 International autoimmune hepatitis group non-response criteria in autoimmune hepatitis: Quick vs. slow responders","volume":"78","author":"Engel","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib302","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/apt.12223","article-title":"Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis","volume":"37","author":"de Boer","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.017_bib303","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/HEP.0000000000000997","article-title":"Optimizing thiopurine therapy in autoimmune hepatitis: a multicenter study on monitoring metabolite profiles and co-therapy with allopurinol","volume":"80","author":"Chung","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib304","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/hep.25760","article-title":"Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis","volume":"56","author":"Dhaliwal","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib305","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0168-8278(05)80615-4","article-title":"Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis","volume":"21","author":"Sherman","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib306","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1572-0241.1999.00807.x","article-title":"Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis","volume":"94","author":"Fernandes","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib307","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1023\/A:1010683817344","article-title":"Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis","volume":"46","author":"Malekzadeh","year":"2001","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.03.017_bib308","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13063-023-07832-w","article-title":"Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response on first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial","volume":"25","author":"Stoelinga","year":"2024","journal-title":"Trials"},{"key":"10.1016\/j.jhep.2025.03.017_bib309","doi-asserted-by":"crossref","first-page":"100189","DOI":"10.1016\/j.jtauto.2023.100189","article-title":"Belimumab treatment in autoimmune hepatitis and primary biliary cholangitis - a case series","volume":"6","author":"Kolev","year":"2023","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.jhep.2025.03.017_bib310","article-title":"Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis","volume":"2","author":"Arvaniti","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.017_bib311","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/00365521.2015.1095351","article-title":"Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on tacrolimus therapy","volume":"51","author":"Than","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib312","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jhepr.2019.10.005","article-title":"Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: results from the international autoimmune hepatitis group","volume":"1","author":"Than","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.017_bib313","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.mcg.0000139050.67178.be","article-title":"Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis","volume":"38","author":"Aqel","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib314","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2012.11.010","article-title":"Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis","volume":"58","author":"Weiler-Normann","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib315","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1111\/liv.15970","article-title":"Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: results from the ColHai registry","volume":"44","author":"Riveiro-Barciela","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib316","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1080\/00365521.2020.1821764","article-title":"Efficacy and safety profile of calcineurin inhibitor salvage therapy in autoimmune hepatitis","volume":"55","author":"Roberts","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib317","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103113","article-title":"Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis","volume":"140","author":"Terziroli Beretta-Piccoli","year":"2023","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhep.2025.03.017_bib318","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/2013\/512624","article-title":"Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy","volume":"27","author":"Burak","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib319","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jhep.2025.03.017_bib320","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jhep.2025.03.017_bib321","doi-asserted-by":"crossref","first-page":"J239","DOI":"10.1016\/j.jaut.2011.12.002","article-title":"Outcomes of pregnancy in women with autoimmune hepatitis","volume":"38","author":"Westbrook","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhep.2025.03.017_bib322","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cgh.2011.03.036","article-title":"Model for end-stage liver disease score predicts outcome in cirrhotic patients during pregnancy","volume":"9","author":"Westbrook","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib323","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1080\/00365521.2021.1953127","article-title":"Systematic review with meta-analysis: autoimmune hepatitis in pregnancy","volume":"56","author":"El Jamaly","year":"2021","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib324","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/apt.16924","article-title":"Systematic review with meta-analysis: outcomes of pregnancy in patients with autoimmune hepatitis","volume":"55","author":"Si","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.017_bib325","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep.32132","article-title":"Outcomes of pregnancy in autoimmune hepatitis: a population-based study","volume":"75","author":"Wang","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib326","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jhep.2023.03.006","article-title":"EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy","volume":"79","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib327","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3109\/00365521.2015.1115893","article-title":"Pregnancy and childbirth in women with autoimmune hepatitis is safe, even in compensated cirrhosis","volume":"51","author":"Danielsson Borssen","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib328","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.cgh.2018.12.030","article-title":"Presentation and outcomes of pregnancy in patients with autoimmune hepatitis","volume":"17","author":"Llovet","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib329","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/00365520601155266","article-title":"Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding?","volume":"42","author":"Werner","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib330","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/liv.12901","article-title":"Increased risk of preterm birth in women with autoimmune hepatitis - a nationwide cohort study","volume":"36","author":"Stokkeland","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib331","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1055\/s-0035-1556743","article-title":"Update on the teratogenicity of maternal mycophenolate mofetil","volume":"4","author":"Coscia","year":"2015","journal-title":"J Pediatr Genet"},{"key":"10.1016\/j.jhep.2025.03.017_bib332","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/liv.15511","article-title":"Importance of complete response for outcomes of pregnancy in patients with autoimmune hepatitis","volume":"43","author":"Fischer","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib333","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.dld.2018.02.015","article-title":"Clinical and prognostic implications of acute onset of autoimmune hepatitis: an Italian multicentre study","volume":"50","author":"Muratori","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2025.03.017_bib334","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6470847","article-title":"Autoimmune hepatitis with acute presentation: clinical, biochemical, and histological features of 126 patients","volume":"2022","author":"Urzua","year":"2022","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib335","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/lt.25451","article-title":"Acute severe autoimmune hepatitis: corticosteroids or liver transplantation?","volume":"25","author":"Rahim","year":"2019","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.03.017_bib336","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jceh.2020.08.007","article-title":"Determinants of outcomes in autoimmune hepatitis presenting as acute on chronic liver failure without extrahepatic organ dysfunction upon treatment with steroids","volume":"11","author":"Sharma","year":"2021","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib337","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jhep.2020.12.033","article-title":"Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: the SURFASA score","volume":"74","author":"De Martin","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib338","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/hep4.1521","article-title":"CLIF-C organ failure score and liver volume predict prognosis in steroid-treated severe acute autoimmune hepatitis","volume":"4","author":"Ikura","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.03.017_bib339","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.dld.2022.08.035","article-title":"Severe acute autoimmune hepatitis: how to early predict who will not respond to corticosteroids and needs urgent liver transplantation?","volume":"54","author":"Joao","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2025.03.017_bib340","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/j.cgh.2021.06.006","article-title":"Early dynamics of MELD scores predict corticosteroid responsiveness to severe acute-onset autoimmune hepatitis","volume":"20","author":"Noguchi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib341","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/apt.16926","article-title":"Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study","volume":"56","author":"Tellez","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.017_bib342","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.MPG.0000158524.30294.E2","article-title":"Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United Kingdom","volume":"40","author":"Lee","year":"2005","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib343","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MPG.0000000000000593","article-title":"Fulminant hepatic failure of autoimmune aetiology in children","volume":"60","author":"Di Giorgio","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib344","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7869\/tg.160","article-title":"Clinicopathological profile and management of severe autoimmune hepatitis","volume":"35","author":"Ramachandran","year":"2014","journal-title":"Trop Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib345","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/apt.17373","article-title":"Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: an international, multicentre, propensity score-matched analysis","volume":"57","author":"Niu","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.017_bib346","doi-asserted-by":"crossref","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","article-title":"Practice parameters committee of the American College of G. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","author":"Chalasani","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib347","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/hep.32689","article-title":"AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury","volume":"77","author":"Fontana","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib348","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2036.2005.02403.x","article-title":"Diagnosis and treatment of autoimmune hepatitis at age 65 and older","volume":"21","author":"Verslype","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.017_bib349","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2169\/internalmedicine.46.0420","article-title":"Clinical features of Japanese elderly patients with type 1 autoimmune hepatitis","volume":"46","author":"Miyake","year":"2007","journal-title":"Intern Med"},{"key":"10.1016\/j.jhep.2025.03.017_bib350","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/jgh3.12451","article-title":"Presence and type of decompensation affects outcomes in autoimmune hepatitis upon treatment with corticosteroids","volume":"5","author":"Sharma","year":"2021","journal-title":"JGH Open"},{"key":"10.1016\/j.jhep.2025.03.017_bib351","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12016-016-8583-2","article-title":"The management of autoimmune hepatitis patients with decompensated cirrhosis: real-world experience and a comprehensive review","volume":"52","author":"Wang","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jhep.2025.03.017_bib352","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2025.02.010","article-title":"Hepatic encephalopathy and MELD-Na predict treatment benefit in autoimmune hepatitis-related decompensated cirrhosis","author":"Arvaniti","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib353","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep4.1467","article-title":"Primary sclerosing cholangitis with features of autoimmune hepatitis: Exploring the global variation in management","volume":"4","author":"Milkiewicz","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.03.017_bib354","series-title":"Liver Immunology: Principles and practice","first-page":"359","article-title":"Primary sclerosing cholangitis \u2013 autoimmune hepatitis overlap","author":"Dalekos","year":"2020"},{"key":"10.1016\/j.jhep.2025.03.017_bib355","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12016-015-8516-5","article-title":"The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis","volume":"50","author":"Yang","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jhep.2025.03.017_bib356","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cgh.2013.09.021","article-title":"Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis","volume":"12","author":"Ozaslan","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib357","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.3390\/jcm9051449","article-title":"Treatment of overlap syndromes in autoimmune liver disease: a systematic review and meta-analysis","volume":"9","author":"Freedman","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jhep.2025.03.017_bib358","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140525","article-title":"Criteria used in clinical practice to guide immunosuppressive treatment in patients with primary sclerosing cholangitis","volume":"10","author":"Schulze","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.03.017_bib359","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jhep.2014.08.002","article-title":"Long-term outcome in PSC\/AIH \"overlap syndrome\": does immunosuppression also treat the PSC component?","volume":"61","author":"Zenouzi","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib360","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2008.03722.x","article-title":"Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival","volume":"28","author":"Al-Chalabi","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.017_bib361","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.510280210","article-title":"Frequency and nature of the variant syndromes of autoimmune liver disease","volume":"28","author":"Czaja","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib362","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1572-0241.2005.41841.x","article-title":"Clinical course and outcome of autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome","volume":"100","author":"Floreani","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib363","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MCG.0b013e318157c614","article-title":"Characteristics and long-term prognosis of the autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome","volume":"43","author":"Luth","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib364","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.cgh.2016.07.032","article-title":"No evidence that azathioprine increases risk of cholangiocarcinoma in patients with primary sclerosing cholangitis","volume":"14","author":"Zenouzi","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib365","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis","volume":"152","author":"Weismuller","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.017_bib366","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1007\/s10620-016-4213-3","article-title":"Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease","volume":"61","author":"De Luca-Johnson","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.03.017_bib367","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MCG.0000000000001817","article-title":"Patients with autoimmune hepatitis and nonalcoholic fatty liver disease: characteristics, treatment, and outcomes","volume":"58","author":"Strzepka","year":"2024","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib368","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1040029","article-title":"Impact of hepatic steatosis on treatment response of autoimmune hepatitis: a retrospective multicentre analysis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.03.017_bib369","first-page":"232","article-title":"Microsomal autoantibodies in chronic infection with the HBsAg associated delta (\u03b4) agent","volume":"54","author":"Crivelli","year":"1983","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jhep.2025.03.017_bib370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.07.006","article-title":"Autoimmune liver disease serology in acute hepatitis E virus infection","volume":"94","author":"Terziroli Beretta-Piccoli","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhep.2025.03.017_bib371","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1478-3231.2008.01851.x","article-title":"Occult hepatitis B virus infection in patients with autoimmune liver diseases","volume":"29","author":"Georgiadou","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib372","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1097\/MPG.0000000000000257","article-title":"Hepatitis C virus-autoimmune hepatitis overlap syndrome in an adolescent","volume":"61","author":"Rosen","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib373","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000531773","article-title":"Autoimmune hepatitis induced by hepatitis delta virus: a Conundrum","volume":"31","author":"Cardoso","year":"2024","journal-title":"GE Port J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib374","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0168-8278(99)80092-0","article-title":"Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment","volume":"30","author":"Dalekos","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib375","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jhep.2021.10.012","article-title":"Safety and effectiveness of up to 3 years\u2019 bulevirtide monotherapy in patients with HDV-related cirrhosis","volume":"76","author":"Loglio","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib376","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/hep4.1388","article-title":"Direct-acting antiviral treatment of patients with hepatitis C resolves serologic and histopathologic features of autoimmune hepatitis","volume":"3","author":"Simoes","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.03.017_bib377","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s12328-023-01809-7","article-title":"Histological improvement in chronic hepatitis C-autoimmune hepatitis overlap syndrome by glecaprevir and pibrentasvir","volume":"16","author":"Matsumoto","year":"2023","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib378","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.017_bib379","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib380","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/1751-2980.12057","article-title":"Prevalence and significance of autoantibodies in patients with alcoholic liver disease","volume":"14","author":"Lian","year":"2013","journal-title":"J Dig Dis"},{"key":"10.1016\/j.jhep.2025.03.017_bib381","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/MPG.0000000000002776","article-title":"Autoimmune hepatitis in children: prednisone plus azathioprine versus cyclosporine: a randomized trial","volume":"71","author":"Cuarterolo","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib382","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/jpn3.12424","article-title":"Current practice in the management of paediatric autoimmune liver disease in Europe","volume":"80","author":"Cananzi","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib383","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/MPG.0b013e3182602b20","article-title":"Autoimmune hepatitis in children in Eastern Denmark","volume":"55","author":"Vitfell-Pedersen","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib384","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14687","article-title":"Live-attenuated vaccination for measles, mumps, and rubella in pediatric liver transplantation","volume":"28","author":"Keutler","year":"2024","journal-title":"Pediatr Transpl"},{"key":"10.1016\/j.jhep.2025.03.017_bib385","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.vaccine.2019.12.024","article-title":"Vaccination rate and immunity of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany","volume":"38","author":"Cagol","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.017_bib386","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13571","article-title":"Live vaccines after pediatric solid organ transplant: proceedings of a consensus meeting, 2018","volume":"23","author":"Suresh","year":"2019","journal-title":"Pediatr Transpl"},{"key":"10.1016\/j.jhep.2025.03.017_bib387","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1651-2227.2012.02745.x","article-title":"Tacrolimus without or with the addition of conventional immunosuppressive treatment in juvenile autoimmune hepatitis","volume":"101","author":"Marlaka","year":"2012","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.jhep.2025.03.017_bib388","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0022-3476(99)70339-2","article-title":"Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis","volume":"135","author":"Debray","year":"1999","journal-title":"J Pediatr"},{"key":"10.1016\/j.jhep.2025.03.017_bib389","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/jpn3.12378","article-title":"Primary sclerosing cholangitis in children with inflammatory bowel disease: an ESPGHAN position paper from the Hepatology Committee and the IBD Porto group","volume":"80","author":"van Rheenen","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib390","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jhep.2022.04.025","article-title":"Children with autoimmune liver disease have limited access to age-appropriate drug formulations, results from a European survey","volume":"77","author":"Jorgensen","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib391","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/MPG.0000000000003513","article-title":"Long-term growth in children and young people with autoimmune liver disease treated with daily steroids","volume":"75","author":"Manwani","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib392","doi-asserted-by":"crossref","first-page":"103321","DOI":"10.1016\/j.jaut.2024.103321","article-title":"The risk of cancer in pediatric-onset immune-mediated inflammatory diseases - a nationwide study","volume":"149","author":"Ehrstrom","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhep.2025.03.017_bib393","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/MPG.0000000000002146","article-title":"Lower 6-MMP\/6-TG ratio may be a therapeutic target in pediatric autoimmune hepatitis","volume":"67","author":"Bolia","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib394","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s40262-024-01393-0","article-title":"Innovating thiopurine therapeutic drug monitoring: a systematic review and meta-analysis on DNA-thioguanine nucleotides (DNA-TG) as an inclusive biomarker in thiopurine therapy","volume":"63","author":"Bayoumy","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jhep.2025.03.017_bib395","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3389\/fped.2019.00382","article-title":"Novel diagnostic and therapeutic strategies in juvenile autoimmune hepatitis","volume":"7","author":"Sciveres","year":"2019","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jhep.2025.03.017_bib396","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1097\/MPG.0000000000001779","article-title":"The best choice for second-line agent in standard treatment-refractory children with autoimmune hepatitis","volume":"66","author":"Nastasio","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib397","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1097\/AOG.0000000000005512","article-title":"Immunosuppressant medications in pregnancy","volume":"143","author":"Saad","year":"2024","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jhep.2025.03.017_bib398","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2013.05.046","article-title":"Infliximab as rescue therapy in paediatric autoimmune hepatitis","volume":"59","author":"Rajanayagam","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib399","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/MPG.0000000000001759","article-title":"Anti-TNFalpha treatment in children and adolescents with combined inflammatory bowel disease and autoimmune liver disease","volume":"66","author":"Nedelkopoulou","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib400","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1542\/peds.2011-1900","article-title":"Successful treatment of refractory autoimmune hepatitis with rituximab","volume":"132","author":"D'Agostino","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.jhep.2025.03.017_bib401","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/MPG.0b013e3181bf0ef7","article-title":"Childhood autoimmune liver disease: indications and outcome of liver transplantation","volume":"50","author":"Chai","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib402","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/MPG.0000000000001927","article-title":"Evolving practice and changing phenotype in pediatric autoimmune liver disease: outcomes from an Australian center","volume":"67","author":"Singh","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib403","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jpeds.2021.07.047","article-title":"Sclerosing cholangitis in pediatric inflammatory bowel disease: early diagnosis and management affect clinical outcome","volume":"238","author":"Hensel","year":"2021","journal-title":"J Pediatr"},{"key":"10.1016\/j.jhep.2025.03.017_bib404","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1097\/MPG.0000000000003858","article-title":"Hepatology committee of the European Society for paediatric Gastroenterology H, Nutrition. Liver biopsy is indicated before attempting treatment withdrawal in children with AIH: commentary by the ESPGHAN HepCom","volume":"77","author":"Samyn","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib405","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1053\/j.gastro.2011.02.065","article-title":"Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center","volume":"140","author":"Hoeroldt","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.017_bib406","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/cld.797","article-title":"Long-term outcomes of autoimmune hepatitis","volume":"14","author":"Gleeson","year":"2019","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.jhep.2025.03.017_bib407","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib408","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib409","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3390\/cancers13051023","article-title":"Current trends and characteristics of hepatocellular carcinoma in patients with autoimmune liver diseases","volume":"13","author":"Rigopoulou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2025.03.017_bib410","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.017_bib411","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/gutjnl-2020-321702","article-title":"Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups","volume":"70","author":"Pinter","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.017_bib412","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2025.03.017_bib413","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2024.101534","article-title":"Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma","author":"Stern","year":"2024","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib414","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/lt.25739","article-title":"Longterm survival after liver transplantation for autoimmune hepatitis: results from the European liver transplant registry","volume":"26","author":"Heinemann","year":"2020","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.03.017_bib415","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/lt.25375","article-title":"Recurrent and de novo autoimmune hepatitis","volume":"25","author":"Stirnimann","year":"2019","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.03.017_bib416","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/LVT.0000000000000419","article-title":"Recurrence of autoimmune liver diseases after liver transplantation: review and expert opinion statement","volume":"31","author":"Montano-Loza","year":"2025","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.03.017_bib417","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/jhep.2000.9077","article-title":"Liver transplantation for autoimmune hepatitis: a long-term pathologic study","volume":"32","author":"Ayata","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib418","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/LVT.0000000000000278","article-title":"Autoimmune hepatitis recurrence after liver transplantation: \u201cLes jeux sont faits\u201d","volume":"30","author":"Chouik","year":"2024","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.03.017_bib419","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jhep.2022.01.022","article-title":"Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation","volume":"77","author":"Montano-Loza","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib420","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/lt.24323","article-title":"Longterm corticosteroid use after liver transplantation for autoimmune hepatitis is safe and associated with a lower incidence of recurrent disease","volume":"22","author":"Krishnamoorthy","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.03.017_bib421","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1111\/ajt.13909","article-title":"2016 comprehensive update of the Banff working group on liver allograft pathology: introduction of antibody-mediated rejection","volume":"16","author":"Demetris","year":"2016","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2025.03.017_bib422","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0140-6736(97)06478-7","article-title":"De-novo autoimmune hepatitis after liver transplantation","volume":"351","author":"Kerkar","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.03.017_bib423","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/j.1478-3231.2012.02832.x","article-title":"Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation","volume":"32","author":"Montano-Loza","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib424","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/lt.21721","article-title":"Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation","volume":"15","author":"Salcedo","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.03.017_bib425","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/liv.13960","article-title":"Autoimmune hepatitis exerts a profound, negative effect on health-related quality of life: a prospective, single-centre study","volume":"39","author":"Janik","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.017_bib426","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1007\/s11136-021-02850-0","article-title":"Health-related quality of life in patients with autoimmune hepatitis","volume":"30","author":"Michel","year":"2021","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jhep.2025.03.017_bib427","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/hep.30031","article-title":"The impact of autoimmune hepatitis and its treatment on health utility","volume":"68","author":"Wong","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.017_bib428","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jhep.2013.10.035","article-title":"Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis","volume":"60","author":"Schramm","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib429","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204772","article-title":"Health-related quality of life in patients with autoimmune hepatitis: a questionnaire survey","volume":"13","author":"Takahashi","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.03.017_bib430","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000022764","article-title":"Quality of life among patients with autoimmune hepatitis in remission: a comparative study","volume":"99","author":"Takahashi","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhep.2025.03.017_bib431","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.4254\/wjh.v13.i11.1642","article-title":"Health-related quality of life in autoimmune hepatitis","volume":"13","author":"Snijders","year":"2021","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib432","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/MPG.0000000000001930","article-title":"Autoimmune hepatitis in children and adolescents: effect on quality of life","volume":"66","author":"Trevizoli","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib433","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jped.2017.10.013","article-title":"Decreased health-related quality of life in children and adolescents with autoimmune hepatitis","volume":"95","author":"Bozzini","year":"2019","journal-title":"J Pediatr (Rio J)"},{"key":"10.1016\/j.jhep.2025.03.017_bib434","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/MPG.0b013e31829ef82c","article-title":"Health-related quality of life in children with autoimmune liver disease","volume":"57","author":"Gulati","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib435","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/archdischild-2023-325675","article-title":"Psychiatric disorders in paediatric-onset immune-mediated inflammatory diseases: a nationwide Danish study","volume":"108","author":"Jansson","year":"2023","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jhep.2025.03.017_bib436","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/lt.24629","article-title":"Liver transplantation and adolescence: the role of mental health","volume":"22","author":"Hames","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.03.017_bib437","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/MPG.0000000000003119","article-title":"Adherence, mental health and illness perceptions in autoimmune liver disease: Looking beyond liver function tests","volume":"73","author":"Hames","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib438","article-title":"Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis","volume":"4","author":"Alrabadi","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.017_bib439","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2169\/internalmedicine.1817-23","article-title":"Zinc supplementation and an improved quality of life in patients with autoimmune hepatitis","volume":"63","author":"Moriya","year":"2024","journal-title":"Intern Med"},{"key":"10.1016\/j.jhep.2025.03.017_bib440","first-page":"CD002098","article-title":"Interactive telemedicine: effects on professional practice and health care outcomes","volume":"2015","author":"Flodgren","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2025.03.017_bib441","doi-asserted-by":"crossref","DOI":"10.2196\/11968","article-title":"Technology-enabled health care collaboration in pediatric chronic illness: pre-post interventional study for feasibility, acceptability, and clinical impact of an electronic health record-linked platform for patient-clinician partnership","volume":"8","author":"Opipari-Arrigan","year":"2020","journal-title":"JMIR Mhealth Uhealth"},{"key":"10.1016\/j.jhep.2025.03.017_bib442","doi-asserted-by":"crossref","first-page":"914","DOI":"10.14309\/ajg.0000000000003179","article-title":"Is ChatGPT-4 a reliable tool in autoimmune hepatitis?","volume":"120","author":"Colapietro","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.017_bib443","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/apt.17904","article-title":"UK guideline on the transition and management of childhood liver diseases in adulthood","volume":"59","author":"Joshi","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.017_bib444","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cld.637","article-title":"Looking after young people with liver conditions: understanding chronic illness management in the context of adolescent development","volume":"9","author":"Darcy","year":"2017","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.jhep.2025.03.017_bib445","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7861\/clinmed.2019-0172","article-title":"Paediatric to adult liver transition services: the state of play in the UK","volume":"19","author":"Joshi","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.jhep.2025.03.017_bib446","doi-asserted-by":"crossref","first-page":"S1000","DOI":"10.1016\/S0168-8278(23)03066-0","article-title":"Current transition management of adolescents and young adults with liver diseases: an European reference network rare liver survey","volume":"78","author":"Madaleno","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.017_bib447","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/pch\/pxw007","article-title":"Expand your HEADS, follow the THRxEADS","volume":"22","author":"Chadi","year":"2017","journal-title":"Paediatr Child Health"},{"key":"10.1016\/j.jhep.2025.03.017_bib448","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0197-0070(91)90084-Y","article-title":"HEADSS, a psychosocial risk assessment instrument: implications for designing effective intervention programs for runaway youth","volume":"12","author":"Cohen","year":"1991","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.jhep.2025.03.017_bib449","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13317-020-0127-3","article-title":"The perspective on standardisation and harmonisation: the viewpoint of the EASI president","volume":"11","author":"Damoiseaux","year":"2020","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.jhep.2025.03.017_bib450","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/MPG.0000000000002930","article-title":"Multiparametric MRI as a noninvasive monitoring tool for children with autoimmune hepatitis","volume":"72","author":"Janowski","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2025.03.017_bib451","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/hep4.1687","article-title":"Multiparametric magnetic resonance imaging, autoimmune hepatitis, and prediction of disease activity","volume":"5","author":"Arndtz","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.03.017_bib452","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-058999","article-title":"LiverMultiScan as an alternative to liver biopsy to monitor autoimmune hepatitis in the National Health Service in England: an economic evaluation","volume":"12","author":"Bajre","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jhep.2025.03.017_bib453","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/apt.18235","article-title":"Low socioeconomic status exacerbates unmet health-related needs in patients with autoimmune hepatitis","volume":"60","author":"Singleton","year":"2024","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825001734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825001734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T21:09:06Z","timestamp":1773349746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825001734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":453,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0168827825001734"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.03.017","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EASL Clinical Practice Guidelines on the management of autoimmune hepatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}